In recent years, there has been an increased interest in the unwanted effects of fenoterol, because with the doses used in clinical practice this 13-agonist can cause more cardiac and systemic side effects than salbutamol and terbutaline.12 The undesirable side effects of fenoterol may aggravate pulmonary gas exchange abnormalities due to increased cardiac output (QT), release of hypoxic pulmonary vasoconstriction and/or increased oxygen consumption (Vo2).3,4
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Procedures
Arterial blood samples were collected anaerobically through catheters inserted into the radial artery. Arterial Po2, Pco2,  Ventilation-perfusion distributions were estimated by the MIGET3-5 without sampling mixed venous inert gases, a modality that can be used with similar accuracy,5'9"10 in the customary manner. 5,11'12 With this approach, QT needs to be directly measured while mixed venous inert gas concentrations are computed from mass balance equations.5"10 The duplicate samples of each set of measurements were treated separately, the final data being expressed as the average of variables determined from both VA/Q distributions at each time point. Maintenance of steady-state conditions after drug nebulization was demonstrated by stability (±+5%) of both ventilatory and hemodynamic variables, and by the close agreement between duplicate measurements of mixed expired and arterial 02 and CO2 (within ±5%). These conditions were met in all patients.
Data Analysis
Data are reported as mean±SD. Because the time course of changes following the different interventions clearly showed maximum responses at different points in time and then return toward baseline conditions, a conventional analysis ofvariance to determine significance of intervention effects was considered inappropriate. Accordingly, the maximum change from baseline for each outcome variable was considered a suitable summary measure of its individual response profile." The latter considers the individual as the basic unit and uses the responses for each subject to construct a single number that summarizes some aspect of that individual's response curve. We chose the maximum change from baseline that may be interpreted as a measure of the maximum effect of each treatment. Since distributions of these summary measures clearly showed skewness, these maximum changes from baseline after each treatment were treated as raw data and compared using one-way analysis ofvariance. This statistical analysis has been previously used by our group to assess the effects of inhaled platelet-activating factor on pulmonary gas exchange in healthy subjects.'4 Differences between treatments for variables considered significant according to the latter approach were then analyzed using an analysis of contrasts. Pearson's correlation analysis was used as appropriate. Significance was set at p2'0.O5. RESULTS
Baseline Findings
Clinical and functional data (Table 1) were similar to those of previous studies in patients with moderate to severe COPD.15 All patients were or had been cigarette smokers. Patients had moderate to severe airflow obstruction with gas trapping, airway hyperinflation, decreased specific airway conductance, and mild to moderate low transfer factor (diffusion of carbon monoxide) (data not included). Ventilatory (f, 16±3 min-1; VE, 8 L/min) variables were within expected limits for these patients, whereas arterial physiologic gases were moderately to severely abnormal (PaO2, 65+8 mm Hg; PaCO2, 37+7 mm Hg; P(A-a)02, 37±8 mm Hg; pH, 7.40±0.03); Vo2 was normal (245+56 mUmin). The VA/Q mismatch was essentially characterized by mild to moderate increases in the dispersions of pulmonary perfusion (second moment) (log SD Q) and ventilation (log SD V) (normal values, 0.3 to 0.616). Shunt (VA/Q ratios <0.005) was conspicuously trivial (0.7±1.3% of QT), there were mild amounts of blood flow diverted to areas with low VA/Q ratios (<0.1, excluding shunt) (8.4+6.7% of QT) but negligible percentages of alveolar ventilation in areas with high VA/Q ratios (>10, excluding dead space) (1.8±3.9% of VA), and dead space (VA/Q ratios >100) was slightly increased (35±11o% of VA). Seven patients showed both broadly unimodal perfusion and ventilation patterns, six showed both bimodal blood flow and ventilation patterns, nine showed a bimodal blood flow profile, and the remaining two showed a bimodal ventilation pattern only. Arterial Po2, and the P (A-a) FEV , increased at all time points moderately (p=0.12) following nebulization of the three bronchodilators as shown in previous studies17 without major differences between interventions (Tables 2 and 3, Fig 1) . Compared with placebo, f, VE, and PS remained essentially unchanged after each intervention, except for a minor increase in f by 3.7±2.7 min-m (mean+SD maximum change from baseline) (p<0.03) after fenoterol-ipratopium, without physiologic significance, which persisted by 120 min.
After fenoterol alone, HR increased by 14.3±5.3 min-1 compared with placebo (p<0.002), ipratropium (p<0.02), and also fenoterol-ipratropium (p<0.003), and showed a trend to return to baseline values at 120 min; compared with placebo, fenoterol alone also increased QT significantly by 1.3±1.4 L/min (p=0.05) to return to baseline values by 120 min. Pulmonary Gas Exchange Responses No significant changes were shown in any of the functional markers of gas exchange after the different treatments (Tables 2 and 3; Fig 1) . However, it is of note that after high-dose fenoterol therapy, PaO2 decreased by 6 .3±1.1 mm Hg (p=0.14) and P(A-a)02 increased by 8.3+±4.0 mm Hg (p=0.16), both variables returning toward baseline values by 120 min. It is also of interest to point that the VA/Q abnormalities after high-dose fenoterol therapy also increased, as evidenced in the dispersion ofpulmonary blood flow (log SD Q) by 0.27±0.26 (p=0.19), which tended to return to baseline values by 120 min; likewise, after low-dose fenoterol therapy, log SD Q also deteriorated by 0.30+0.20 without associated changes in arterial oxygenation. No other changes were shown in any of the inert gas variables, including the various dispersion indexes considered to be well-known descriptors of VA/Q heterogeneity.9 It has been suggested that CHESTI 110/1 /JULY, 1996 73 Figure 2 illustrates the individual responses of the most relevant variables after high-dose fenoterol therapy; the separate effects of low-dose fenoterol therapy were identical on FEV1, similar but less marked on Vo2 and log SD Q, and trivial on PaO2 and QT. There were no significant correlations between the changes in PaO2 and log SD Q observed after both high-and low-dose fenoterol therapy and their corresponding baseline values. Similarly, there were no significant correlations between the increases in QT and changes in log SD Q.
DISCUSSION
The cardinal finding of our study was that inhaled fenoterol given to hypoxemic patients with stable COPD, especially at high dose, increased HR and QT and maybe also reverted hypoxic pulmonary vasoconstriction. The increased pulmonary blood flow or the vasodilation in hypoxic lung areas, or both, caused further VA/Q worsening, as assessed by the increased dispersion of pulmonary blood flow (log SD Q), an index sensitive to both below-normal and low VA/Q ratios. This in turn resulted in accentuated COPD, our group has shown that the lower the hypoxic vascular response, the greater the thickness of the intimal layer of the pulmonary vessels.27 This structural derangement interferes with the adaptability of the pulmonary vasculature to vasoactive drugs, hence to the maintenance of an adequate VA/Q matching. We have also shown that, in patients with COPD who had recovered from exacerbations, IV aminophylline had no effect on VA/Q distributions despite the presence of an active hypoxic vascular response. 28 Despite the fact that fenoterol-induced pulmonary gas exchange variations lacked statistical significance, it may be legitimate to speculate with the idea that the tendency to decrease PaO2 (after a high dose only) and to increase both the P(A-a)02 and the dispersion of pulmonary blood flow can be related to an increased QT and/or to an additional vasodilator effect, ie Heart rate (min-') 
